Gefitinib Inhibits the Growth and Invasion of Urothelial Carcinoma Cell Lines in which Akt and MAPK Activation Is Dependent on Constitutive Epidermal Growth Factor Receptor Activation

Nicolle, Gaëlle; Daher, Ahmed; Maillé, Pascale; Vermey, Marcel; Loric, Sylvain; Bakkar, Ashraf; Wallerand, Hervé; Vordos, Dimitrios; Vacherot, Francis; Gil Diez De Medina, Sixtina; C Abbou, Claude; Van der Kwast, Theodore; Thiery, Jean-Paul; Radvanyi, François; K Chopin, Dominique

MSAR Home
→
MSA University Academic Research
→
Research Papers, Articles and Books Chapters.
→
Faculty of Biotechnology Research Paper
→
View Item

Gefitinib Inhibits the Growth and Invasion of Urothelial Carcinoma Cell Lines in which Akt and MAPK Activation Is Dependent on Constitutive Epidermal Growth Factor Receptor Activation

Nicolle, Gaëlle; Daher, Ahmed; Maillé, Pascale; Vermey, Marcel; Loric, Sylvain; Bakkar, Ashraf; Wallerand, Hervé; Vordos, Dimitrios; Vacherot, Francis; Gil Diez De Medina, Sixtina; C Abbou, Claude; Van der Kwast, Theodore; Thiery, Jean-Paul; Radvanyi, François; K Chopin, Dominique

Full Text link: https://cutt.ly/krHztO6

Date issued: 2006

Scientific Journal Rankings: Click Here

Doi: https://doi.org/10.1158/1078-0432.CCR-05-2148

Publisher: American Association for Cancer Research

Series Info: Clinical cancer research;VOL : 12 Issue : 9

Type: Article

Keywords: University for Gefitinib Inhibits , Carcinoma , Cell Lines , MAPK Activation , Factor Receptor

Abstract:

Abnormally high levels of epidermal growth factor receptor (EGFR) protein are associated with advanced tumor stage/grade. The objective of this study was to evaluate the effects of the specific EGFR tyrosine kinase inhibitor gefitinib on activation of the Akt and mitogen-activated protein kinase (MAPK) pathways in human urothelial cell carcinoma (UCC) cell lines and to identify potential markers of gefitinib responsiveness in biopsy samples of UCC.